- Tilray report fourth-quarter earnings after Monday’s closing bell.
- Analysts are expecting an adjusted loss of $1.34 a share on $15 million revenue.
- Watch Tilray trade live.
The cannabis producer Tilray is set to report fourth-quarter earnings after Monday’s closing bell. Here are the key numbers, compared with what analysts surveyed by Bloomberg were expecting.
- Adjusted loss per share: $0.33 versus $1.34 expected
- Revenue: $15.5 million versus $15.07 million expected
- 2019 adjusted-loss-per-share guidance: $0.376
- 2019 revenue guidance: $188.05 million
“2018 was a very successful year for Tilray with many corporate milestones. Our team made significant progress on our long-term initiatives including increasing production capacity, expanding and strengthening strategic partnerships, and acquiring complementary businesses to accelerate our future growth and leadership position in medical and adult-use cannabis,” commented Brendan Kennedy, President and Chief Executive Officer of Tilray. “Looking ahead, we remain committed to pursuing global growth opportunities and will be disciplined in deploying capital, particularly in the United States and Europe, where we believe we have multiple paths for value creation.”
Tilray debuted for trading on the Nasdaq in July, becoming the first cannabis company to have an initial public offering in the US. Since then, it has sped up developing its business.
In December, Tilray announced a partnership with a division of the Swiss drug giant Novartis AG, hoping to commercialize its non-smokable medical-cannabis products, develop new products, and educate pharmacists and physicians about cannabis.
In January, the company said it planned to acquire the cultivator Natura Naturals. The deal will allow Tilray to expand its capacity to supply high-quality branded cannabis products to the Canadian market.
Tilray shares were little changed this year through Monday.